Hi. This is Dr. Anne Peters, from the University of Southern California. Today I'm going to talk about the new American College of Cardiology/American Heart Association (ACC/AHA) guidelines[1] for the treatment of dyslipidemia and risk for cardiovascular disease.
Many of you have probably already read these guidelines and have some understanding about what they mean. I want to discuss them from my perspective as a clinician and then discuss how they affect patients with diabetes.
First of all, I want to commend the authors for doing this -- for trying to write new evidence-based guidelines that really shift how we think about the treatment of lipid disorders. As one of the authors of the new diabetes position statement on the treatment of hyperglycemia, I know how hard it is both to review the evidence as well as to come away with conclusions that can help guide our treatment of patients.
The key to these new guidelines is to not look at numbers as targets but rather to look at risk, to see which of our patients are at highest risk for cardiovascular events, and then to treat them accordingly.
Medscape Diabetes © 2013 WebMD, LLC
Cite this: How Do New Statin Guidelines Affect Diabetes Care? - Medscape - Nov 21, 2013.
A Look Ahead to ACC 2022: Late-Breaking Clinical Trials in Lipid Management
Fast Five Quiz: Lipids Management: High HDL Cholesterol Levels (Hyperalphalipoproteinemia)
AACE Issues 'Cookbook' Algorithm to Manage Dyslipidemia
COMMENTARY
How Do New Statin Guidelines Affect Diabetes Care?
Anne L. Peters, MD
DisclosuresNovember 21, 2013
Hi. This is Dr. Anne Peters, from the University of Southern California. Today I'm going to talk about the new American College of Cardiology/American Heart Association (ACC/AHA) guidelines[1] for the treatment of dyslipidemia and risk for cardiovascular disease.
Many of you have probably already read these guidelines and have some understanding about what they mean. I want to discuss them from my perspective as a clinician and then discuss how they affect patients with diabetes.
First of all, I want to commend the authors for doing this -- for trying to write new evidence-based guidelines that really shift how we think about the treatment of lipid disorders. As one of the authors of the new diabetes position statement on the treatment of hyperglycemia, I know how hard it is both to review the evidence as well as to come away with conclusions that can help guide our treatment of patients.
The key to these new guidelines is to not look at numbers as targets but rather to look at risk, to see which of our patients are at highest risk for cardiovascular events, and then to treat them accordingly.
Medscape Diabetes © 2013 WebMD, LLC
Cite this: How Do New Statin Guidelines Affect Diabetes Care? - Medscape - Nov 21, 2013.
Tables
References
Authors and Disclosures
Authors and Disclosures
Author
Anne L. Peters, MD
Professor of Clinical Medicine; Director, Clinical Diabetes Programs, Keck School of Medicine, University of Southern California, Los Angeles, California
Disclosure: Anne L. Peters, MD, has disclosed the following financial relationships:
Served as director, officer, partner, employee, advisor, consultant, or trustee for: (current consultant): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk
Served as a speaker or member of a speakers bureau for: (current speakers bureau member): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a consultant or ad hoc speaker/consultant for: AstraZeneca Pharmaceuticals LP; Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Dexcom; Medtronic MiniMed, Inc.; Merck & Co., Inc.; Roche; sanofi-aventis